Thu. 22 Feb 2024, 7:05am ET
Benzinga
Earnings, News
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.69) by 1.45 percent. This is a 6.67 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $24.23 million which missed the analyst consensus estimate of $25.38 million by 4.52 percent. This is a 175.70 percent increase over sales of $8.79 million the same period last year.